Bezpieczeństwo wirusologiczne stosowania czynników krzepnięcia w leczeniu hemofilii A

*Roman Hożejowski, Beata Kozłowska

Summary
Currently used plasma derived factor concentrates are far safer than those available in the 1980?s and early 1990?s which transmitted HIV, hepatitis B and C viruses. Purification methods and viral inactivation procedures used in the manufacturing process are effective in relation to lipid-enveloped viruses, yet non-lipid-enveloped viruses (eg. B19 Parvovirus) or proteinaceous infectious particles (prions) are highly resistant and at least theoretically can continue to be transmitted through blood products. The risk of appearance of the emerging pathogens which are resistant to the current inactivation methods is unknown. A step towards the improved safety of factor VIII concentrates was the introduction of recombinant factors, made by genetic engineering. For the sake of further enahancement of microbiological safety, human albumin was abandoned as stabilizer of recombinant factors and replaced with sucrose. Recombinant clotting factors have now been used for 17 years and there has not been a single infection reported in that time.

To jest tylko fragment artykułu. Aby przeczytać całość, przejdź do Czytelni medycznej.